Bellus Health (TSX:BLU)(NASDAQ:BLU) is a $397.17 million clinical-stage biopharmaceutical

Bellus Health (TSX:BLU)(NASDAQ:BLU) is a $397.17 million clinical-stage biopharmaceutical company from Laval, Canada. It develops therapeutics for the treatment of chronic cough, chronic pruritus, and other hypersensitization disorders. The company’s lead drug candidate, BLU-5937, is now in phase two clinical trial. Bellus Health President and CEO Roberto Bellini anticipate a transformative year ahead following the significant progress with the clinical development of BLU-5937 over the past 12 months. Management believes its lead drug candidate has the potential to treat a wide range of hypersensitization-related conditions. Source: https://ca.finance.yahoo.com/news/2-tsx-stocks-could-return-133625109.html 

back

Bellus Health (TSX:BLU)(NASDAQ:BLU) is a $397.17 million clinical-stage biopharmaceutical

bullish

Bellus Health (TSX:BLU)(NASDAQ:BLU) is a $397.17 million clinical-stage biopharmaceutical company from Laval, Canada. It develops therapeutics for the treatment of chronic cough, chronic pruritus, and other hypersensitization disorders. The company's lead drug candidate, BLU-5937, is now in phase two clinical trial.

Bellus Health President and CEO Roberto Bellini anticipate a transformative year ahead following the significant progress with the clinical development of BLU-5937 over the past 12 months. Management believes its lead drug candidate has the potential to treat a wide range of hypersensitization-related conditions.

Source: https://ca.finance.yahoo.com/news/2-tsx-stocks-could-return-133625109.html

read-time
< 1 min
5.46
Target Price
10/ 10
Confidence
2-6 Months
Timeframe
catalyst icon
Earnings Release
catalyst icon
News
catalyst icon
SEC
Filing
catalyst icon
Sentiment
catalyst icon
Other Catalyst

Access the latest tools and discussion channels with an account

reddit-sentiment

Reddit Sentiment
Analysis

portfolio-balancer

Portfolio Balancer
with brokerages

sec-dashboard

SEC Dashboard
with NLP

*/}aiodd-ad
next